` OPTN (OptiNose Inc) vs S&P 500 Comparison - Alpha Spread

OPTN
vs
S&P 500

Over the past 12 months, OPTN has significantly outperformed S&P 500, delivering a return of +60% compared to the S&P 500's +13% growth.

Stocks Performance
OPTN vs S&P 500

Loading
OPTN
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
OPTN vs S&P 500

Performance Gap Between OPTN and GSPC
HIDDEN
Show

Performance By Year
OPTN vs S&P 500

Loading
OPTN
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
OptiNose Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

OptiNose Inc
Glance View

Market Cap
97.2m USD
Industry
Pharmaceuticals

OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 189 full-time employees. The company went IPO on 2017-10-13. The firm's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.

OPTN Intrinsic Value
HIDDEN
Show
Back to Top